Anzeige
Meldung des Tages: Das Triple-Discovery-Setup, das der Markt noch nicht begriffen hat!!

TransCode Therapeutics News

Aktie
WKN:  A4170U ISIN:  US89357L5012 US-Symbol:  RNAZ Branche:  Biotechnologie Land:  USA
10,53 $
+0,00 $
0,00%
9,0378 € 10.02.26
Depot/Watchlist
Marktkapitalisierung *
4,98 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

TransCode Therapeutics News

03.03.26 - PR Newswire
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-​Free License to Develop and Commercialize a Next-​Generation Oncolytic Immunotherapy Platform in an All-Stock ...
23.02.26 - PR Newswire
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development PR Newswire
05.02.26 - PR Newswire
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 PR Newswire
06.01.26 - PR Newswire
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma PR Newswire
22.12.25 - PR Newswire
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors PR Newswire
11.12.25 - PR Newswire
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-​expansion trial with TTX-MC138, following positive readouts from TransCode's ...
17.11.25 - PR Newswire
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer PR Newswire
14.10.25 - PR Newswire
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO PR Newswire
08.10.25 - PR Newswire
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-​in-class unique ...
28.05.25 - PR Newswire
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board PR Newswire

Newssuche

Videos

newspaper
04.03.26 +1,73%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »